We’ve recently updated our valuation analysis.

NIOX Group Valuation

Is NIOX undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

6/6

Valuation Score 6/6

  • Price-To-Earnings vs Peers

  • Price-To-Earnings vs Industry

  • Price-To-Earnings vs Fair Ratio

  • Below Fair Value

  • Significantly Below Fair Value

  • Analyst Forecast

Key Valuation Metric

Which metric is best to use when looking at relative valuation for NIOX?

Other financial metrics that can be useful for relative valuation.

NIOX key valuation metrics and ratios. From Price to Earnings, Price to Sales and Price to Book to Price to Earnings Growth Ratio, Enterprise Value and EBITDA.
Key Statistics
Enterprise Value/Revenue4.9x
Enterprise Value/EBITDA48.6x
PEG Ratio-1.4x

Price to Earnings Ratio vs Peers

How does NIOX's PE Ratio compare to its peers?

The above table shows the PE ratio for NIOX vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
CompanyPEEstimated GrowthMarket Cap
Peer Average36.1x
BVXP Bioventix
24.4x4.6%UK£187.5m
GNS Genus
49.2x16.2%UK£2.0b
OPTI OptiBiotix Health
3.2xn/aUK£18.9m
ANCR Animalcare Group
67.5x-53.1%UK£135.2m
NIOX NIOX Group
11.6x-8.6%UK£153.1m

Price-To-Earnings vs Peers: NIOX is good value based on its Price-To-Earnings Ratio (11.6x) compared to the peer average (36.1x).


Price to Earnings Ratio vs Industry

How does NIOX's PE Ratio compare vs other companies in the European Biotechs Industry?

0 CompaniesPrice / EarningsEstimated GrowthMarket Cap
Industry Avg.n/a24.4%
n/an/an/a

Price-To-Earnings vs Industry: NIOX is good value based on its Price-To-Earnings Ratio (11.6x) compared to the European Biotechs industry average (26.8x)


Price to Earnings Ratio vs Fair Ratio

What is NIOX's PE Ratio compared to its Fair PE Ratio? This is the expected PE Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

NIOX PE Ratio vs Fair Ratio.
Fair Ratio
Current PE Ratio11.6x
Fair PE Ratio20.5x

Price-To-Earnings vs Fair Ratio: NIOX is good value based on its Price-To-Earnings Ratio (11.6x) compared to the estimated Fair Price-To-Earnings Ratio (20.5x).


Share Price vs Fair Value

What is the Fair Price of NIOX when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Below Fair Value: NIOX (£0.37) is trading below our estimate of fair value (£0.85)

Significantly Below Fair Value: NIOX is trading below fair value by more than 20%.


Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

The above table shows the analyst NIOX forecast and predictions for the stock price in 12 month’s time.
DateShare PriceAverage 1Y Price TargetDispersionHighLow1Y Actual priceAnalysts
CurrentUK£0.36
UK£0.48
+30.6%
12.0%UK£0.55UK£0.41n/a3
Nov ’23UK£0.38
UK£0.48
+25.8%
12.0%UK£0.55UK£0.41n/a3
Oct ’23UK£0.36
UK£0.44
+21.2%
6.8%UK£0.47UK£0.41n/a2
Sep ’23UK£0.34
UK£0.44
+29.4%
6.8%UK£0.47UK£0.41n/a2
Aug ’23UK£0.35
UK£0.44
+26.6%
6.8%UK£0.47UK£0.41n/a2
Jul ’23UK£0.34
UK£0.46
+35.8%
12.1%UK£0.51UK£0.40n/a2
Jun ’23UK£0.35
UK£0.46
+28.3%
12.1%UK£0.51UK£0.40n/a2
May ’23UK£0.35
UK£0.46
+28.5%
12.1%UK£0.51UK£0.40n/a2
Apr ’23UK£0.36
UK£0.46
+26.4%
12.1%UK£0.51UK£0.40n/a2
Mar ’23UK£0.37
UK£0.40
+8.1%
0%UK£0.40UK£0.40n/a1
Feb ’23UK£0.42
UK£0.40
-4.9%
0%UK£0.40UK£0.40n/a1
Jan ’23UK£0.41
UK£0.40
-1.5%
0%UK£0.40UK£0.40n/a1
Dec ’22UK£0.38
UK£0.40
+5.4%
0%UK£0.40UK£0.40n/a1
Apr ’22UK£0.30
UK£0.21
-30.0%
0%UK£0.21UK£0.21UK£0.361
Mar ’22UK£0.25
UK£0.21
-16.8%
0%UK£0.21UK£0.21UK£0.371
Feb ’22UK£0.25
UK£0.21
-15.2%
0%UK£0.21UK£0.21UK£0.421
Jan ’22UK£0.28
UK£0.21
-25.5%
0%UK£0.21UK£0.21UK£0.411
Dec ’21UK£0.29
UK£0.21
-26.4%
0%UK£0.21UK£0.21UK£0.381
Nov ’21UK£0.22
UK£0.21
-3.0%
0%UK£0.21UK£0.21UK£0.431

Analyst Forecast: Target price is more than 20% higher than the current share price and analysts are within a statistically confident range of agreement.


Discover undervalued companies